GEN Exclusives

More »

GEN News Highlights

More »
Oct 26, 2012

Atara Established to Develop Amgen Assets

  • Amgen and Kleiner Perkins Caufield & Byers (KPCB) have founded a new drug development firm, Atara Biotherapeutics, focused on chronic diseases in therapeutic areas including nephrology and oncology. Atara will start out with licenses to six of Amgen’s preclinical and early-clinical programs.

    The new firm will initially be financed by KPCB, and headed by former KPCB partner, Isaac Ciechanover, M.D. Amgen will retain a minority equity interest in Atara.

    “Amgen is excited to partner with KPCB to help advance molecules in Amgen’s pipeline that have the potential to treat serious illnesses,” comments Sean E. Harper, M.D., Amgen’s executive vp for R&D. With facilities in both the Bay Area and near Amgen's Thousand Oaks campus, Atara Biotherapeutics will provide the opportunity to further foster biotechnology innovation in Amgen’s communities. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?